Trial
NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
—
Condition
Acute Leukemia
Intervention
Thymoglobulin
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-30